moral arm of the immune system (1). Such Well abnormalities appear to be multifactorial in origin, with demonstration of both intrinsic B-cell defects and defects secondary to CD4+ helper dysfunction (1-4). Functional abnormalities of B lymphocytes noted in vitro include elevated spontaneous proliferation, increased numbers of spontaneous plaque-forming cells in the peripheral blood, enhanced responsiveness to B-cell growth factors, and refractoriness to normal in vitro signals for B-cell activation (1). In vivo manifestations of dysfunction include hypergammaglobulinemia, circulating immune complexes, an inability to mount an appropriate serologic response after immunization, and an increased frequency of common bacterial and viral infections.
Although B-and T-cell dysfunction are seen in both HIVinfected adults and children, the consequences of B-cell dysfunction may be more pronounced in children, particularly those with vertically a c q W infection. In adults, even if response to new antigens is diminished, preexisting memory cells provide some immunity fiom infection with common pathogens. However, if defective B-cell function occurs early in life, before the development of specific memory cells, recurrent and severe infection with otherwise common organisms may result.
In children with HIV infection, recurrent infection with cod mon bacterial and viral organisms is a frequent and early manifestation of HIV disease. The similarity of the type of infections seen in HIV-infected children to those seen in children with congenital hypogammaglobulinemia provided the early rationale for use of IVIG for infection prophylaxis in pediatric HIV infection. This article briefly reviews the problem of and the immunologic pxdkposition for recurrent infections in HIV infected children and summarizes the published reports on the use of M G for infection prophylaxis, including updated and newly analyzed data from the NICHD IVIG Clinical Trial. Although the focus of this article is on the use of IVIG for preexposure prophylaxis of infections, other current and potential uses for M G in pediatric HIV infection include treatment of HIVassociated thromboqtopenia, treatment of cytomegalovirus and Parvovirus B19 infection, and the potential use of hyperimmune HIV immune globulin for treatment of HIV in fection and prevention of vertical tnmmkion (5,6).
RECURRENT INFECTIONS IN HIV-INFECTED CHILDREN
HIV infection in adults is associated with the development of infections with relatively rare, opportunistic organisms. In contrast, the development of recurrent serious systemic illness caused by common encapsulated bacteria is so common in HIV-infected children that the federal CDC modified the pediatric AIDS case definition in 1987 to include recurrent serious bacterial infections as an AIDSindicator disease (7). Although PCP is the most frequent AIDS-defining illness in children, recurrent serious bacterial infections occurred in almost 25% of children with ----
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years of follow-up. The overall incidence of infections is summarized in Table 2 . Serious laboratory-proven or clinically di- , lu r.r r.n O.M r.0
Using events occumng through the date of trial termination, increased significance was observed for M G in prolonging in- The most frequent laboratory-proven infections were primary bacderemias (74%) and pneumonia (22%). Similar to other reports, the most common bacterial isolate was pneumococcus, accounting for 28% of all isolates. In patients with an entry CD4+ count of 200/mm3 or higher, the rate of invasive pneum o c d disease per 100 patient-years was 5.7 episodes in pla- ccbo patients compared with 2 0 in M G patients (Table 3) . counts of 200/md or lugher, five occumd in placebo and two in M G patients who were k v i q PCP prophylaxis at least 1 mo before the event occurred, and eight occurred in placebo and three in M G patients who were not receiving prophylaxis before the event. Although the overall o c m n c e of serious infections with other bacteria was also decreased with M G , infections with other bacterial species were too few to make meaninm individual comparisons.
M G w a s~w i t h a~i n p n c u m~d i s e a s e
Acute pneumonia was the most common clinically diagnosed serious infection (6674, followed by acute sinusitis. There was a 53% decrease in the rate of acute clinically diagnosed pneumonia per 100 patient-years in IVIG recipients with entry CD4+ counts of 200/mm3 or higher (Table 3) .
Six h u n d d forty-nine minor bacterial infedions were ob w e d in 205 children with entry CD4+ counts of 200/mm3 or higher. Nearly 60% involved the ear, 13% skin and soft tissue, and 10% upper respiratory tract. S i t l y fewer minor bae terial infections per 100 patient-years occumd with M G in patients with entry CD4+ counts of 200/mm3 or higher ( p = 0.02) ( Table 3) . IVIG was associated with decreases in rates per 100 patient-yean of 36% for otitis, 39% for skidsoft tissue infections, and 32% for upper respiratory tract i n f ' Similarly, significantly fewer viral infections pg 100 patient-I years were observed with M G in patients with entry CW+ counts of 200/mm3 or higher ( p = 0.01) ( Table 3) . Two hundred twelve viral infections were diagnosed in 129 -t s in this group. Of infections with a spedfled etiology, over 50% were due t 0 h e r p w S i m p l e x v i r w .~w e r e 4 5 % f~h a p c s s i m~ virus infections in M G tecipients. For viral infdoos with a spedled etiology, t h m agents for which humoral immunity is and C shows group 2 chiMren ( p = 0.0035). The &ted proporti; of chiidren in each study arm d n g infection-free at 6, 12, 18, and 24 mo is indicated beneath eacb g%aph.
traditionally associated with prevention of infection were decreased in IVIG recipients. All five of the reported cases of measles, two of two enteroviral infections, and the single case of hepatitis A occurred in placebo patients.
There were 55 opportunistic infections in 34 patients with entry CD4+ counts of 200/mm3 or higher. The most frequent infection was with Candida, accounting for 73% of infections, followed by PCP (7%); all other etiologies accounted for 5% or less. There was a similar frequency of opportunistic infections in M G and placebo children (Table 3) .
Detailed analysis has been done to evaluate the interaction of M G and concomitant therapy with trimethoprim/sulfamethoxazole administered 3 d/wk for PCP prophylaxis or w i t h ZDV (41). As of January 199 1, when the study ended, 50% of study patients with an entry CD4+ count of 200/mm3 or higher had received PCP prophylaxis (50% of placebo and 49% of IVIG patients) and 45% had received ZDV (47% of placebo and 44%
of M G patients). Time to initiation of either therapy was similar in both groups. A proportional hazards analysis was performed to look for po6sii interactions between M G and either PCP prophylaxis or ZDV thtrapy in terms of time to first serious bacterial infection. S~c a l l y , PCP prophylaxis and ZDV therapy were used as tinmedependent covaiates (22). The resulting analysis indicated that the previously discussed effect of M G was of the same magnitude before and after the use of either PCP prophylaxis a ZDV. ZDV use was assaciated with a nonsigmtlcant prolongation of time to serious badmid infection, whereas PCP prophylaxis was asochted with a d e w in time to serious bactmkl infection, prnrumsbly a reflection that children who developed infections were more Iikely to be pIaced on prophylaxis.
DISCUSSION
Treatment with M G was safe and well tolerated, with benefit seen across sewed idmious outcome parameters. In M Gtreated children who entend the trial with a CD4+ count of 200/mm3 or higher, treatment significantly increased the time fne from serious bactcd infections and significantly reduced the number of minor b a c t d infections and viral infections (42).
As in other studies, S. pneumoniae was the most common identified etiology of serious bacterial infection; M G therapy was associated with a 62% decrease in pneumococcal disease in patients with entry CD4+ counts of 200/mm3 or higher. PCP prophylaxis as adminkred in this study and cumntly recommended by the Public Health Service (trimethoprim/sulfamethoxazole given 3 d/wk) (22) did not appear to significantly affect the incidence of pneumococcal disease or alter the benefit of IVIG. However, the influence of a daily regimen of antibiotic prophylaxis remains to be determined.
Repeated episodes of acute pneumonia cause significant morbidity in HIV-infected children. In a recent report, 70% of a cohort of HIV-infected children fiom New York City required hospital admission for an acute respiratory illness with no identified pathogen, and 30% developed laboratory-proven bgcterial pneumonia (1 5). In our study, acute pneumonia, the majority clinically diagnosed, was the most frequently observed serious infection. The rate of acute laboratory-proven or clinically diagnosed pneumonia episodes in placebo-arm patients with entry CD4+ counts of 200/mm3 or higher (26 episodes per 100 patientyears) was more than 6 times greater than that reported for healthy preschool children (43). IVIG therapy was associated with a 53% decrease in acute laboratory-proven bacterial or clinically diagnosed pneumonia episodes per 100 patient-years in patients with entry CD4+ counts of 200/mm3 or higher.
Viral infections were a significant cause of morbidity in this cohort. M G therapy was associated with a significant decrease in viral infections, particularly herpes simplex virus, in patients with entry CD4+ counts of 200/mm3 or higher. Although cellular immunity is thought to play a major role in prevention of recurrent herpes simplex infection, recent data have suggested that antibodydependent cellular cytotoxicity may also play a significant role (44,45). It would be anticipated that a protective effect of antibody would therefore depend upon a relatively intact cellular immune system, as might be seen in those children with CD4+ counts of >2W/mm3.
Limitations of IVIG therapy were noted. In group 2 patients, there was some delay before a treatment effect was seen for serious infections. This may be related to the low incidence of events in these patients, who had less advanced HIV disease, and the likelihood that infectious complications may not increase in frequency until immunologic attrition occurs, i.e. loss of T-helper recall antigen response (29). In addition, because the half-life of IgG is reduced in hypergammaglobulinemic states (46), attainment of a month-long protective effect of IVIG may be delayed in HIV-infected patients. In patients with primary immunodeficiency receiving monthly IVIG, serum IgG levels show a stepwise increase in peak and trough levels after the fmt four to six infusions before reaching a protective plateau (47). The optimal dose and frequency of IVIG administration in pediatric HIV infection remains to be determined. Further data analysis to evaluate the timing of infectious events in relation to time of IVIG infusion is planned.
In children who entered the trial with CD4+ counts of <200/ mm3, no significant improvement was noted. The limited number of children with entry CD4+ counts of C200/mm3 (50 total patients) decreases the power of this study to detect such a diffetrmce and conclusions regarding the effectiveness of M G in this population cannot be drawn from this study. However, it is possible that adjunctive immunotherapy with M G is most effective in those children with mild-to-moderate immunologic dysfunction with some preservation of T-helper cell function. In such children, therapy may compensate for defects in T-helper recall antigen response and provide protection against a variety of bacterial and viral pathogens through provision of specific antibody as well as enhancement of antibodydependent cytotoxicity. As immunologic function continues to deteriorate, the combination of CD4+ cell depletion coupled with severe dysfunction of the residual T-helper cell population may be too severe to overcome through provision of antibody alone. Therapies that may be succxdd at one level of immune dysfunction may not be d c i e n t with increasing levels of dysfunction.
ACTG PROTOCOL 05 1
Although ZDV therapy during the NICHD M G Clinical Trial did not alter the results, the NICHD trial was not designed to evaluate the efficacy of IVIG in children already receiving ZDV.
The National Institutes of Health is also sponsoring a double blind, placebocontrolled trial to evaluate M G in children with severely symptomatic HIV infection (AIDS or AIDS-related complex) receiving ZDV (ACTG protocol 05 1). This trial, which has completed enrollment with 262 patients, closed to accrual on August 16, 1990 and is currently ongoing. The sample size requirements of ACTG 051 assume an infection rate of 25% after 24 mo and an M G treatment effect of 60%; lower infection rates or treatment effects less than 60% may limit the ability of the trial to detect a significant treatment difference. The observed overall treatment effect of IVIG in the NICHD M G Clinical Trial at the time of study termination was 39%; however, the patient population in the NICHD trial was less severely symp tomatic than that in ACTG 05 1.
In some studies, ZDV has been demonstrated to improve Thelper and other immune cell function (48-50). Although the immunologic correlates of infection risk in HIV-infected children have not been well delineated, it is possible that ZDV, by delaying the time to immunologic deterioration, could prolong an infection "risk-fk" period, during which adjunctive immunotherapy may not be necessary. Further evaluation of data from the NICHD IVIG Clinical Trial, as well as A C E 05 1, may better delineate the subgroup of HIV-infected children most likely to benefit from M G therapy.
It is important to note, however, that the effect of ZDV in enhancing immunologic and clinical status appears to be transient (5 1,52). Because the natural history of HIV infection, even in the treatment era, appears to be one of progressive immuno deficiency, serial combinations of antiretroviral therapy, antibi otic prophylaxis to prevent PCP, imrnunomodulator therapy such as M G , and other adjunctive therapies may be necessary to prevent the eventual development of a downward cycle of increasingly opportunistic infections in the HIV-infected child. Dr. Mofenson: I wish that we had cells saved; however, we do have serum saved from the children. When the study was designed in 1987, the issues around differential loss of recall antigen were not as well known. It would be very interesting to look at recall and alloantigen function in these children, but we just do not have the cells to do that.
Dr. Steigbigel: Although you observed a decrease in a variety of measures of bacterial infection, the time to death did not change. Was there an analysis of what the causes of death were and was there a substitution of different causes in one group versus the other? Dr. Mofenson: We have not done an analysis by cause of death. While the study was ongoing, we presented a paper at ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy) about the diagnosis of pneumonia in study children. At that time, a briefblinded review ofdeath for pneumonia was done. We found that most of the deaths were associated with opportunistic infection. There were maybe one or two deaths that I remember reviewing in which sepsis or bacterial infection was the primary cause of death. There were a number of deaths that were due to cardiomyopathy, nephropathy, some that were due to Candida, meningitis, or CMV (cytomegalovirus) disease, but very few were related to bacterial infections per se. We need to go back and do a blinded, independent review of cause of death to do that curve over again.
Dr. Steigbigel: So in that the time to death was not changed, the benefit in terms of the total patient care would have to rest a lot on quality-of-life issues.
Dr. Mofenson: Yes. Dr. Steigbigel: Do you have any data on the total hospital time, including the time that the patient is hooked up to IVIG? Dr. Mofenson: The IVIG was administered as outpatient therapy. We do have data on hospital days, and it was reported in our original paper. There were significantly fewer hospitalizations in the IVIG-treated patients. We limited ourselves to acute care hospitalization and found about 38 fewer hospitalizations per 100 patient-years in the IVIG group. I would like to go back and look at cause of hospitalization because I think it would be even more significant if we looked specifically at infection-related hospitalizations.
Dr. Rubinstein: From 1979 to 198 1, we treated children with pediatric AIDS without knowing that they had pediatric AIDS, knowing only that they had a B-cell deficiency. We gave IVIG in the same manner as our treatment of agammaglobulinemic patients and we found that the once-monthly regimen did not give us the same benefit as more frequent regimens. I recall one child who had three recurrent episodes of pneumococcal sepsis, each one at the end of the period after receiving IVIG. We looked at levels of pneumococcal antibodies in this child 4 wk after the previous gamma globulin infusion, and they were nonexistent. That was why we moved to more frequent infusions, and we still continue that regimen in those of our children who are not in your study. Those in your study receive IVIG once monthly, but those that are on our study are given IVIG every other week.
The second finding that was obvious in the studies was that we did not see the immunomodulatory effect of IVIG in the same manner as we do in CVID (common variable immunodeficiency). One of the parameters we looked at was immune complexes. When we gave the IVIG once monthly, as reported in our paper in 1985, the immune complexes went down, only to bounce back up after 4 wk to the same level as before. When we gave IVIG more frequently, we could reduce circulating immune complexes only with a biweekly infusion. My question to you is, now that you have analyzed the infections and shown that the increased infection rate appears at the longest interval after the infusion, would you recommend a more frequent infusion of IVIG to these children?
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Dr. Mofenson: Well, as I have said, this is very preliminary data. I saw the data on rate of infection from time of infusion only a few days ago. It is just an initial run and we are looking at a variety of different things. I think that this study did not answer all the questions; I think it has raised even more questions. The optimal dose, the optimal timing, the optimal population remain to be decided. I am hoping that when the other ACTG trial (051) is over we will sit down together, compare the data and the patient populations, and hold a concensus conference to be able to help the clinician know what to do. When people ask me now, my answers are as a clinician and not as an NIH staff member! I will be happy to do that away from the microphone. Dr. Wara: All I hope is that when this consensus conference is held you all can figure out a way to infuse IVIG no more frequently than once a month, because we are not going to be able to handle it otherwise.
Dr. Stiehm: I have never seen a case of varicella on IVIG. I am wondering if there were extenuating circumstances; for example, could these children have had severe diarrhea and lost all their gamma globulin if they got the varicella at the end of the period, or did they have extremely high levels ofgamma globulin, which greatly increases IVIG catabolism? It would be interesting to analyze those specific cases.
Dr. Mofenson: I have divided them into primary varicella and zoster. Some of those primary varicellas may be the phenomenon called recurrent varicella. When you think about the use of IVIG versus hyperimmune globulin, you don't give IVIG when you are trying to prevent varicella, you give hyperimmune VZIG (varicella-zoster immune globulin); but when you want to prevent measles, you give immune serum globulin. I think it says something about the concentration of antibody that may be needed to prevent infections in the two groups. After thinking about the difference between herpes simplex and varicella and about the fact that we give VZIG, I was not completely surprised that there were a similar number of cases. It was somewhat less in the IVIG-treated group but not significantly less.
Dr. Stiehm: VZIG is given intramuscularly and IVIG, of course, gives about a comparable level of antibody. There have been studies on that.
Dr. Fischer: You showed a very interesting association between the IVIG and the change in the decline of the CD4 counts. You may already know the answer to an important question. That is, is this a specific effect of IVIG on organisms, thus decreasing episodes of infection in these children? Did those who had decreased episodes have less decline in CD4 counts, or did all the children, even those who did not have a decreased number of episodes or very few infections, also have a decline in CD4 counts? That could be very important in deciding which IVIG should be used.
Dr. Mofenson: The CD4 count data has also just been analyzed. The problem is that one has to define which infections to consider in the analysis. Serious bacterial infections occurred in 38% of the children, but minor infections occurred in almost 70% and viral infections occurred in about 38-40%. So if you put them all together, almost everybody had an infection at some point. We could try to pull out the IVIG effective group for some definition of infections and look, but we have not done that yet.
Dr. Fischer: One thing that we found, and you have probably seen it too, is that it seems some of the children tend to have a majority of the infections, whereas others will have some infections, but there are really two different groups. That might be worth looking at. 
